Research Pipeline

WE ARE DEVELOPING NOVEL FULLY HUMAN ANTIBODIES FOR ALZHEIMER’S TREATMENT:

​

Amyloid-beta oligomers (Aßo) are involved in starting Alzheimer's disease (AD). The cellular prion protein (PrPC) acts as a receptor for Aßo, causing damage to synapses. Previous research supports the idea that a fully human monoclonal antibody targeting PrPC could be a therapeutic option, potentially modifying the disease by protecting synapses and memory function from Alzheimer's pathology.

 

Our technology focuses on PrPC as a key player in the synaptic dysfunction caused by AB-oligomers in neurodegenerative diseases like Alzheimer's and prion-related conditions such as CJD. The complex signaling cascade includes Aßo/PrPC interaction, activating mGluR5, Fyn, and Pvk2 pathways. Importantly, anti-PrPC monoclonal antibodies improve behavior in an Alzheimer's transgenic mouse model, offering promise for treating advanced disease scenarios with a short treatment duration.

 

Our advanced human monoclonal antibody approach shows potential for addressing the intricate pathophysiology of neurodegenerative disorders, including Alzheimer’s and CJD.